FDA Clears Aletta Robotic Blood-Draw Device After 94.5% First-Stick Success

Q: What triggers the hidden safety mechanism in this new robotic blood-drawer when a patient suddenly moves?

It is triggered by excessive patient movement during the blood draw. According to the FDA and supporting reports, Aletta has a built-in safety mechanism that automatically detaches the needle and stops the procedure if the patient moves too much. The device also uses onboard sensors to detect other unsafe conditions, which can pause the draw and alert the supervising phlebotomist. So if a patient suddenly shifts enough to create a safety risk, the robot responds by disengaging the needle and halting the collection.

3 articles · Updated · Monthly Prescribing Reference · Aug 20

ADOPT data from 1,633 routine-use patients backed the FDA’s authorization, showing Aletta achieved a 94.5% first-stick success rate with only 0.6% mild adverse events.
A separate 153-patient cohort found no statistically significant differences between Aletta- and manually collected samples across key lab measures, supporting comparable test quality.
90% of patients reported less or equivalent pain versus manual draws, and 82% said they would prefer Aletta or had no preference.
Under phlebotomist supervision, the device uses near-infrared imaging and Doppler ultrasound to find veins, then applies the tourniquet, disinfects, inserts and disposes of the needle, and bandages the site.
Vitestro said one phlebotomist can oversee up to 3 machines, a setup the FDA authorization could use to ease staffing shortages and cut wait times.